Novo Nordisk, the corporate behind Ozempic and Wegovy, printed a brand new evaluation of the longest research it has carried out to this point via the lens of long-term weight reduction.
The 17,604-person research, printed in Nature Medication and introduced on the European Congress on Weight problems in Venice, Italy on Tuesday, confirmed for the primary time that weight problems sufferers with out diabetes maintained a ten% common weight reduction over 4 years after taking Wegovy.
“We see that after the vast majority of the load loss is accrued, you do not return and begin to improve in weight for those who keep on the drug,” Martin Holst Lange, Novo’s improvement head, advised Reuters in an interview.
The findings present that Wegovy is efficient in the long run, over a number of years, supplied sufferers keep on it.
Associated: Novo Nordisk Is Value Extra Than Denmark’s GDP Due to America’s Ozempic and Wegovy Craze
A further evaluation launched Tuesday based mostly on the identical knowledge confirmed that Wegovy had advantages for the center, no matter how a lot weight research contributors misplaced whereas taking it.
Wegovy decreased the danger of stroke by 20% in obese or overweight folks with a historical past of coronary heart illness.
Researchers do not exactly know the way Wegovy’s lively ingredient, semaglutide, protects the center, and are conducting research to grasp it.
“We now additionally perceive that whereas we all know that physique weight reduction is vital, it isn’t the one factor driving the cardiovascular advantage of semaglutide remedy,” Lange advised Reuters on Tuesday.
Associated: These U.S. Well being Insurers Will Now Cowl Wegovy, the Wildly Fashionable $1,349 Weight-Loss Drug
The information may add to Novo’s case to have its weight reduction medicine be extra broadly coated by insurance coverage firms in nations just like the U.S. and the U.Ok.
Nonetheless, there have been downsides to taking Wegovy recorded within the report — about 17% of those that took the drug left the research early due to stomach-related points like nausea.
Novo has made Wegovy obtainable in 10 nations to this point, together with the U.S., Norway, Japan, and Spain, since releasing the drug in 2021. Costs begin at $200 and might attain nearly $2,000 per thirty days, relying on the nation.
Within the U.S., Ozempic goes for about $936 a month out of pocket whereas Wegovy sells for about $1,350 a month.
Costco created a program in April that offers members direct entry to Ozempic and Wegovy when applicable, although the medicine price falls straight on prospects or medical health insurance.
Associated: Costco Declares Ozempic, Wegovy Prescriptions and New Weight Loss Program
Novo mentioned earlier this month that a minimum of 25,000 folks within the U.S. begin Wegovy per week.
